Molecular Medicine |
From the Department of Medicine (M.L.N., K.V.V., E.B., P.F.B.) and the Program in Cellular and Molecular Medicine (M.L.N.), Johns Hopkins University School of Medicine, Baltimore, Md.
Correspondence to Paul F. Bray, MD, Baylor College of Medicine, Thrombosis Research Section, Department of Medicine, One Baylor Plaza, BCM 286, Room N1319, Houston, TX 77030. E-mail pbray{at}bcm.tmc.edu
AbstractPlatelets
play an important role in the coronary thrombus formation that leads to
myocardial ischemia and infarction. Gender differences in the
development of coronary heart disease and its outcomes are partly
regulated by estrogen and its receptors, but the roles of the latter in
thrombogenicity are less well-defined. We previously demonstrated the
presence of estrogen receptor (ER) ß in cells of the megakaryocytic
lineage. In this study, we characterize human platelet ERß and its
expression using biochemical and molecular biological techniques.
Western immunoblotting showed that platelet ERß migrated with an
apparent molecular mass
3.7 kDa larger than ERß in a variety of
cell lines (including those of prostate and breast origin). A rigorous
investigation of platelet ERß mRNA by reverse
transcriptasepolymerase chain reaction revealed normal transcripts
and a single alternately spliced mRNA. However, this variant form was
smaller, lacking exon 2, and could not account for the larger protein
size seen in platelets. Treatment of ERß with
N-glycosidase F, which removes
core carbohydrate residues, caused a more rapid migration through
polyacrylamide gels but had no effect on ERß from human cell lines.
We conclude that the larger form of ERß in human platelets is not
attributable to alternate mRNA splicing but primarily to
tissue-specific
glycosylation.
Key Words: platelet estrogen receptor glycosylation
This article has been cited by other articles:
![]() |
K. Aschbacher, R. von Kanel, P. J. Mills, S. Hong, S. K. Roepke, B. T. Mausbach, T. L. Patterson, M. G. Ziegler, J. E. Dimsdale, S. Ancoli-Israel, et al. Combination of Caregiving Stress and Hormone Replacement Therapy is Associated With Prolonged Platelet Activation to Acute Stress Among Postmenopausal Women Psychosom Med, November 1, 2007; 69(9): 910 - 917. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Vitseva, D. A. Flockhart, Y. Jin, S. Varghese, and J. E. Freedman The Effects of Tamoxifen and Its Metabolites on Platelet Function and Release of Reactive Oxygen Intermediates J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1144 - 1150. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Q. Chen, M. Delannoy, C. Cooke, and J. D. Yager Mitochondrial localization of ER{alpha} and ER{beta} in human MCF7 cells Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E1011 - E1022. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Maccarrone, M. Bari, N. Battista, and A. Finazzi-Agro Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation Blood, December 1, 2002; 100(12): 4040 - 4048. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |